medigraphic.com
ISSN 1405-8871 (Print)

2014, Number 2

<< Back Next >>

Aten Fam 2014; 21 (2)

Family Factors that Favor Adherence to Treatment of Pulmonary Tuberculosis Cases

Martínez-Hernández YO, Guzmán-López F, Flores-Pulido JJ, Vázquez-Martínez VH

Language: Spanish
References: 16
Page: 47-49
PDF size: 255.86 Kb.


ABSTRACT

Objective: identify the family factors that favor adherence to treatment of Pulmonary Tuberculosis (ptb). Material and methods: observational, descriptive, cross-sectional and prospective study made at the Family Medicine Unit (fmu) no. 33 in Reynosa, Tamaulipas, Mexico. All patients diagnosed with ptb, as first time, were included and selected through a nominal census. Results: there were identified 57 patients with ptb. A prevalence of 0.02%, with a predominance of males (56%) of the patients was determined. The minimum age was 18 years and the maximum of 83, with an average of 39±12 years, trend to 26 years and medium of 50.5 years; 85% of the patients began with a shortened treatment strictly supervised (stss), 66.6% of them cured by the end of the treatment, 19.2% continued in retreat and 12% abandoned treatment; 92.2% referred affectation in his personal life after being diagnosed of ptb. Patients with neglect treatment 75% presented some level of family dysfunction. Conclusions: prevalence of ptb at the fmu was of 0.02%, figure remarkably lower than the national average, which is 15 per 100 000 inhabitants. There were high levels of family dysfunction and social rejection in patients with abandon to the treatment than in those with a diagnosis of cure, who presented more familiar functionality.


REFERENCES

  1. Alvarez-Gordillo GC, Alvarez-Gordillo JF, Dorantes-Jiménez JE, Halperin-Frisch D. Percepciones y prácticas relacionadas con la tuberculosis y la adherencia al tratamiento en Chiapas, México. Salud Pública Méx. 2000;42(6):520-8.

  2. Mariscal A, Ramírez-Palacios C, Fuentes-Domínguez J. Conocimiento de tuberculosis pulmonar en pacientes y sus contactos en Veracruz, México. Salud de la comunidad. 2007;3(6):22-32.

  3. García de Alba-García JE, Rubel AJ, Moore CC, Márquez-Amezcua M, Casasola S, Von Glascoe C. Algunos aspectos antropológicos del encuentro médico-paciente con tuberculosis pulmonar en el occidente de México. Gac Méd Méx. 2002;138(2):211-6.

  4. Martínez-Medina MA. Efecto del tratamiento acortado estrictamente supervisado (taes) sobre la adherencia y la tasa de curación de la tuberculosis pulmonar. Gac Méd Méx. 2004;140(1):1-6.

  5. Carrada-Bravo T. Perspectivas en tuberculosis: Sugerencias para su eliminación en la República Mexicana. Rev Inst Nal Enf Resp Mex. 2002;15(2):102-25.

  6. Olvera Castillo R, Ramos Espinosa J, García Cruz AE. Tratamiento antituberculoso ultracorto (2HRZ/2H3R3) versus tratamiento estándar (2HRZ/4H3R3) en combinación fija bajo la estrategia taes. Rev Inst Nal Enf Resp Mex. 2002;15(4):214-9.

  7. Cáceres-Manrique FM. Factores de riesgo para abandono (no adherencia) del tratamiento antituberculoso. Medunab. 2004;7(21):172-80.

  8. Secretaría de Salud. Modificación a la Norma Oficial Mexicana nom-006-ssa2-1993, Para la prevención y control de la tuberculosis en la atención primaria a la salud [Internet]. Disponible en: http://www.aemep.mex.tl/imagesnew/6/5/6/9/0/Norma%20Oficial%20Mexicana%20NOM-006-SSA2-1993,%20tuberculosis.pdf

  9. Martínez Mendoza D, López Segundo E, Torres Cruz A. Consideraciones a los resultados de tratamiento en pacientes con tuberculosis resistente múltiples fármacos (tb mdr). Una revisión de la literatura. Neumología y Cirugía de Tórax. 2008;67(1):34-43.

  10. Marco A, Caylá JA, Serra M, Pedro R, Sanrama C, Guerrero R, et al. Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners. Eur Respir J. 1998;12(4):967-71.

  11. Murray JF. Tuberculosis and hiv infection. Global perspectives. Respirology. 1997;2:209-13.

  12. World Health Organization tb program. tb, a global emergency: who report on the tb epidemic. Ginebra: who/tb; 1994. p. 94-117.

  13. Global tuberculosis control: Surveillance, planning, financing. Geneva: who; 2007.

  14. Alvarez-Gordillo GC, Halperin-Frisch D, Blancarte-Melendres L, Vázquez Castellanos JL. Factores de riesgo para resistencia a drogas antifímicas en Chiapas, México. Salud Pública Méx. 1995;37:408-16.

  15. Eurotb and the National coordinators for tuberculosis surveillance in the who European Region. Surveillance of tuberculosis in Europe. Report in tuberculosis cases notified in 2005. Saint-Maurice: Institut de Veille sanitaire; March 2007.

  16. Gómez-Clavelina FJ, Ponce-Rosas ER. Una nueva propuesta para la interpretación de Family Apgar (versión en español). Aten Fam. 2010;17(4):102-6.




2020     |     www.medigraphic.com